Table 2.
Comparison of responses to questions in the knowledge and practice domain before and after the educational intervention
| Question* | Response (Pre-training) [N=147] | Response (Post-training) [N=121] | Absolute/Relative change | p value** |
|---|---|---|---|---|
| Provider able to identify the 4 major statin benefit groups (item 20) | 64 (43.54%) | 100 (82.64%) | 39.1%/89.8% | 0.0002 |
| Provider aware of the threshold of ≥7.5% 10-year ASCVD risk to initiate discussion regarding risks and benefit of statin therapy (item 6) | 70 (47.62%) | 118(97.52%) | 49.9%104.8% | 0.0002 |
| Provider understands the 4 outcomes captured by the pooled cohort ASCVD risk estimator (item 7) | 23 (15.65%) | 82 (67.77%) | 52.12%/333% | 0.0002 |
| Providers knows the differences between the ATP-III guideline recommend Framingham 10-year CHD risk estimator and the 2013 ACC/AHA recommended 10-year ASCVD risk estimator (item 8) | 13 (8.84%) | 48 (39.67%) | 30.83%/348.7% | 0.0002 |
| Provider able to identify a patient with LDL-C ≥190 mg/dL as possible FH and start a risk discussion regarding statin therapy (item 18) | 48 (32.65%) | 103 (85.12%) | 52.47%/160.7% | 0.0002 |
| Provider understand the definition of low, moderate and high intensity statin therapy as per the 2013 guideline (item 21) | 38 (25.85%) | 95 (78.51%) | 52.66%/203.7% | 0.0002 |
| Provider believes that a repeat lipid panel should be performed within 6–8 weeks in a patient with MI recently started on statin therapy (item 22) | 52 (35.37%) | 75 (61.98%) | 26.61%/75.23% | 0.0002 |
| Provider uses LDL-C as target of therapy (item 16) | 94 (63.95%) | 58 (47.93%) | 16.02%/25% | 0.0118 |
| Provider incorrectly identifies positive family history as one of the variables used in the 10-year ASCVD risk calculation (item 5) | 83 (56.46%) | 19 (15.70%) | 40.76%/72.2% | 0.0002 |
*
Please see questionnaire in supplemental digital appendix.
**
Adjusted for multiple comparisons
ACC = American College of Cardiology, AHA = American Heart Association, ASCVD= atherosclerotic cardiovascular disease, ATP = Adult Treatment Panel, CHD = coronary heart disease, LDL-C = low density lipoprotein cholesterol, FH = familial hypercholesterolemia, MI = myocardial infarction